Business
Board Changes
Surgical Innovations Group PLC announced changes to its Board of Directors, effective immediately. Roy Davis has been appointed as Non-Executive Chair, while Andrew Boteler and Duncan Soukup join as Independent Non-Executive Director and Non-Executive Director, respectively. Simultaneously, Jonathan Glenn and Keyvan Djamarani stepped down from their roles as Non-Executive Chair and Non-Executive Director. Duncan Soukup's related company, Thalassa Holdings Ltd, holds 214,480,101 ordinary shares, representing 22.99% of the company's total voting rights as of September 12, 2025, making them the largest shareholder. Disclaimer*
About this update from Surgical Innovations Group Plc
[{"type":"text","content":"\n\nSurgical Innovations Group plc\n(\"Surgical Innovations\", the \"Company\", or the \"Group\")\n \nBoard Changes\n \nSurgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery (\"MIS\"), announces an evolution to the Board of Directors of the Company as detailed below.\n \nThe Company announces the appointments of Roy Davis, Andrew Boteler and Duncan Soukup as Non-Executive Chair, Independent Non-Executive Director and Non-Executive Director respectively, with immediate effect.\n \nSimultaneously, Jonathan Glenn and Keyvan Djamarani will step down from the Board as Non-Executive Chair and Non-Executive Director respectively with immediate effect. Jonathan and Keyvan joined the Board in 2023 and during this time have been instrumental in the driving the operational review of the business.\n \nRoy joins the Board with a mandate to work alongside the current Executive Directors, David Marsh and Brent Greetham to drive value creation for shareholders over the medium term.\n \nRoy Davis\n \nRoy is an experienced executive with over 35 years of global experience in a variety of industries including medtech, diagnostics and technology sectors. He is currently Chairman of Inspiration Healthcare Group plc, a leading neonatal respiratory company, and Foster & Freeman Ltd (the trading name of the Galton group of companies), a leading forensic imaging manufacturer. He is also a Non-Executive Director of Futura Medical plc, a UK pharmaceutical company focussed on the sexual health market and a Senior Advisor to Moore Walker Partners, a Healthcare & Technology Advisory Services company. Roy was previously Chairman of LunglifeAI plc, Medica Group plc until its sale to IK Partners in 2023 and Chairman of Edinburgh Molecular Imaging Ltd and RAIR Health Ltd.\n \nBefore these Non-Executive roles Roy served as the Chief Executive Officer of Optos plc, a leading ophthalmology medical device business, from 2008 until June 2016 when he stepped down following the company's acquisition by Nikon Corporation. Before joining Optos, he served from 2007 as Chief Executive Officer of Gyrus Group plc, a leading medical device company, prior to its acquisition by the Olympus Corporation of Japan in 2008, having previously...